Más contenido relacionado
Similar a Angle parsortix presentation 07oct11 (20)
Angle parsortix presentation 07oct11
- 1. An Introduction to PARSORTIX
Presented by:
Andrew Newland, Chief Executive
Shane Booth, CEO, Parsortix
7 October 2011
- 2. Major medical diagnostic development for ANGLE
Parsortix
Patented technology for
separating rare cells from blood
Forward-Looking Statements
This presentation and the associated commentary contains certain forward-looking statements
based on current expectations, forecasts and assumptions that involve significant risks and
uncertainties. These statements are based on information currently available to the Company; and
ANGLE / Parsortix's actual results could differ materially from those stated or implied, due to risks
and uncertainties associated with its business.
Forward-looking statements include statements regarding expectations, beliefs, intentions or
strategies regarding the future and can be identified by forward-looking words such as “potential”,
“target”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”,
and “would” or similar words. ANGLE assumes no obligation to update the information included in
this presentation, whether as a result of new information, future events or otherwise.
© ANGLE plc 2011 Page 2
- 3. Market for circulating tumour cell (CTC) separation device
Use of CTC cell counting (simple product) for:
− Research product (does not need regulatory approval)
− Monitoring patient response to chemotherapy
− Monitoring patients in remission to identify CTC ahead of secondary tumours
1.2 million new cancer patients per annum in the US market alone*
− Each patient may need to be monitored over 30 times
Target: potential therapeutic application for a product recovering cells
− A pressing need for CTC recovery in relation to lung, pancreatic, and colo-rectal
cancers as tumour access for biopsy difficult
− These cancers account for approximately one third of the total number of cases
annually in the US
ANGLE may develop the product initially cancer by cancer
*Source : US National Cancer Institute in 2010
© ANGLE plc 2011 Page 3
- 5. Captured cells: whole blood control and spiked with SK-Br-3
Control
Spiked with
breast cancer
cells
© ANGLE plc 2011 Page 5
- 6. Chromogenic staining of SK-Br-3 cells
Stained breast
Cancer cells
Visual ID
breast cancer
cells
Identified cells marked using cytokeratin-18
© ANGLE plc 2011
- 7. Development Plan
Finalise work on characterising the separation device including flow and
volume capability
Finalise market requirements for device
Optimise design of separation device (next generation)
Establish collaboration with cancer research centre(s)
Separation of CTCs from cancer patient blood
Beta test next generation separation device
Final design of separation device
Manufacture in quantity
Initiate sales for research purposes
Target for completion mid 2012
© ANGLE plc 2011 Page 7
- 8. Newsflow potential
Quarter ended 31-Oct-11 31-Jan-12 30-Apr-12 31-Jul-12 31-Oct-12 31-Jan-13 30-Apr-13 31-Jul-13
Continue and expand sales for research purposes
Establish Optimise Initiate sales
collaborative separation for research Comparative studies to support FDA and CE Mark
research with cassette and purposes submission
leading Cancer consumable FDA/CE Mark
Centres in the US design approval
Validation of
and UK
initial findings
Parsortix Advance
discussions with
(completed)
Corporate Partners
Consider joint Corporate deal/
Capture CTCs in
development distribution
cancer patient Establish world
programmes partner finalised Target for
blood leading Scientific
with Corporate clinical product
Advisory Board
Partners launch and sales
Acolyte Completion of Judgement on ANGLE decision on Potential for 3M
Biomedica Acolyte case Acolyte case case against 3M settlement
Launch of Completion of
Potential for
Geomerics Battlefield3 and milestone 3 for
trade sale
Need for Speed major corporate
Potential for Potential for
Retrospective Prospective study
Novocellus milestone product sales
study results results
payments and royalties
= key value triggers
© ANGLE plc 2011 Page 8
- 9. Near-term commercial potential
Target sales launch of product for research purposes mid 2012
− No requirement for regulatory approval
− Immediate market potential
− Astra Zeneca 20,000 separations p.a. with one research lab
− Early sales potential $25m p.a.
Target FDA approval of product for clinical use mid 2013
Clinical market for “simple counting product” estimated at $4bn p.a. in US
market alone
Gross margin in excess of 75%
Significant corporate interest for collaboration with more complex products
The key is a simple, effective product
© ANGLE plc 2011 Page 9
- 10. Legal disclaimer
The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment
(without notice), verification and completeness.
This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on,
directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided to
recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether
orally or in writing, in connection with the Company. Neither this document or any part of this document nor any copy of it
may be sent to or taken into the United States of America, Canada, Australia, Japan, the Republic of South Africa or the
Republic of Ireland, nor may it be distributed to, directly or indirectly, to any US person (within the meaning of regulation S
promulgated under the United States Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does not
constitute an offer to buy or to subscribe for, or the solicitation of an offer to buy or to subscribe for securities in the
Company. To the extent this document is received or used in jurisdictions outside the UK, any such recipient or user should
inform themselves about and observe any applicable legal requirements. Neither this document nor any part of this document
should be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic
transmission, to persons with addresses in the United States of America (or any of its territories or possessions) Canada,
Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationals thereof, or to
any corporation, partnership or other entity created or organised under the laws thereof or in any other country outside the
United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distribution
could result in violation of the laws of such countries.
This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to
purchase any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for
any purpose whatsoever on the information, representation or opinions.
This document should not be considered as the giving of investment advice by the Company or any of its shareholders,
directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own
independent assessment of the Company after making such investigations and taking such advice as may be deemed
necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of
subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.
Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the
accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept
any responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or
otherwise arising in connection therewith.
© ANGLE plc 2011 Page 10